Injection Site Reactions Are the Most Common Adverse Effect of PCSK9 Inhibitors
The most commonly associated adverse effect with PCSK9 inhibitor therapy is injection site reactions, occurring in less than 5% of patients and typically being mild in severity. 1
Primary Adverse Effects
Injection Site Reactions
- Injection site reactions occur in <5% of patients treated with PCSK9 inhibitors and are predominantly very mild in intensity with no cumulative effect over time. 1
- High certainty evidence from systematic reviews (32 trials, 65,861 participants) demonstrates an increase in injection-site reactions leading to discontinuation at a rate of 15 per 1000 patients over five years. 2
- Real-world data confirms injection site reactions as the most frequent adverse event, reported in 33.8% of patients in hospital registries. 3
Musculoskeletal Symptoms
- Myalgia represents the second most common adverse event, reported in 8.3-12.8% of patients in pharmacovigilance databases. 3, 4
- PCSK9 inhibitors show a favorable safety profile compared to statins, with annualized muscle symptom rates of 4.7% versus 8.5% with standard statin therapy. 1
- Real-world pharmacovigilance data demonstrates lower hospitalization rates (15.64% vs 36.83%) and death rates (0.72% vs 3.53%) compared to statins for musculoskeletal events. 5
Influenza-Like Illness
- Influenza-like illness was reported in 27.9% of patients in real-world hospital registries. 3
Important Safety Considerations
What PCSK9 Inhibitors Do NOT Cause
High certainty evidence demonstrates no increase in the following adverse events: 2, 1
- Liver enzyme elevations - No increase in hepatic transaminases observed
- Hypoglycemia or hyperglycemia - No effect on glycated hemoglobin levels or fasting plasma glucose, even in diabetic patients on insulin
- Colon cancer - No association with malignancy
- Neurocognitive events - The EBBINGHAUS trial specifically demonstrated no cognitive impairment even with LDL-C levels <25 mg/dL
- New-onset diabetes - Similar rates to standard therapy (2.8% vs 4.0%), though Mendelian randomization studies suggest potential long-term risk requiring further observation
Discontinuation Rates
- Only 7% of patients discontinued PCSK9 inhibitor treatment due to adverse events in real-world settings. 3
- Most adverse events (71.1%) resolved during follow-up without requiring discontinuation. 3
Clinical Context
The adverse effect profile of PCSK9 inhibitors is remarkably favorable compared to the options listed in your question. None of the serious adverse effects mentioned (colon cancer, hypoglycemia, marked liver enzyme elevation, or hyperglycemia) are associated with PCSK9 inhibitor therapy. 2, 1 The primary concern remains local injection site reactions, which are typically mild, self-limited, and rarely lead to treatment discontinuation.